Advertisement

Topics

$ARQL Clinical Data from Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with R/R Hematologic Malignancies #ASH18 https://www.businesswire.com/news/home/20181203005307/en/ArQule-Announces-Clinical-Data-Ongoing-Phase-1 …

07:12 EST 3 Dec 2018 | Odi Bruckman

Clinical Data from Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with R/R Hematologic Malignancies https://www.businesswire.com/news/home/20181203005307/en/ArQule-Announces-Clinical-Data-Ongoing-Phase-1 …

Original Article: $ARQL Clinical Data from Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with R/R Hematologic Malignancies #ASH18 https://www.businesswire.com/news/home/20181203005307/en/ArQule-Announces-Clinical-Data-Ongoing-Phase-1 …

NEXT ARTICLE

More From BioPortfolio on "$ARQL Clinical Data from Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with R/R Hematologic Malignancies #ASH18 https://www.businesswire.com/news/home/20181203005307/en/ArQule-Announces-Clinical-Data-Ongoing-Phase-1 …"

Advertisement
Quick Search
Advertisement
Advertisement